Disease · MONDO_0016532
Comparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 16 of 16
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Dravet Syndrome vs Lennox-Gastaut Syndrome: deaths from any cause | 6 of 315 | 12 of 366 | 681 | NCT02224573 | Trial comparisons |
| Dravet Syndrome vs Lennox-Gastaut Syndrome: serious adverse events | 133 of 315 | 157 of 366 | 681 | NCT02224573 | Trial comparisons |
| Soticlestat vs Placebo: deaths from any cause | 0 of 134 | 0 of 136 | 270 | NCT04938427 | Trial comparisons |
| Soticlestat vs Placebo: serious adverse events | 11 of 134 | 10 of 136 | 270 | NCT04938427 | Trial comparisons |
| GWP42003-P 20 mg/kg/Day Dose vs Placebo: Number Of Participants With a ≥50% Reduction From Baseline in Drop Seizure Frequency During The Treatment Period | 38 of 86 | 20 of 85 | 171 | NCT02224690 | Trial comparisons |
| GWP42003-P 20 mg/kg/Day Dose vs Placebo: serious adverse events | 20 of 86 | 4 of 85 | 171 | NCT02224690 | Trial comparisons |
| TAK-935 vs Placebo: deaths from any cause | 0 of 71 | 0 of 70 | 141 | NCT03650452 | Trial comparisons |
| TAK-935 vs Placebo: serious adverse events | 11 of 71 | 13 of 70 | 141 | NCT03650452 | Trial comparisons |
| Clobazam Low Dose vs Clobazam High Dose: serious adverse events | 1 of 32 | 3 of 36 | 68 | NCT00162981 | Trial comparisons |
| Rufinamide (E2080) vs Placebo: serious adverse events | 1 of 29 | 1 of 30 | 59 | NCT01146951 | Trial comparisons |
| Rufinamide vs Any Other Approved Antiepileptic Drug: deaths from any cause | 1 of 25 | 0 of 12 | 37 | NCT01405053 | Trial comparisons |
| Rufinamide vs Any Other Approved Antiepileptic Drug: serious adverse events | 10 of 25 | 5 of 12 | 37 | NCT01405053 | Trial comparisons |
| Tuberous Sclerosis Complex vs Dravet Syndrome: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 2 of 2 | 1 of 1 | 3 | NCT04485104 | Trial comparisons |
| Tuberous Sclerosis Complex vs Dravet Syndrome: deaths from any cause | 0 of 2 | 0 of 1 | 3 | NCT04485104 | Trial comparisons |
| Tuberous Sclerosis Complex vs Dravet Syndrome: Number of Participants With Emergence of New Types of Seizures | 1 of 2 | 0 of 1 | 3 | NCT04485104 | Trial comparisons |
| Tuberous Sclerosis Complex vs Dravet Syndrome: serious adverse events | 2 of 2 | 0 of 1 | 3 | NCT04485104 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0016532/comparisons